biostudies-literatureZeng LNCATS NIH HHSNIA NIH HHSNational Institute on Aginge6108https://www.ebi.ac.uk/biostudies/studies/S-EPMC11265565biostudies-literatureUnknown39(6)<h4>Objectives</h4>To examine clinically important adverse events (AEs) associated with methylphenidate (MPH) treatment of apathy in Alzheimer's Disease (AD) versus placebo, including weight loss, vital signs, falls, and insomnia.<h4>Methods</h4>The Apathy in Dementia Methylphenidate Trial 2 (ADMET2) trial was a multicenter randomized, placebo-controlled trial of MPH to treat apathy in individuals with apathy and AD. Participants in ADMET2 had vital signs and weight measured at monthly visits through 6 months. AEs, including insomnia, falls, and cardiovascular events, were reported at every visit by participants and families using a symptom checklist.<h4>Results</h4>The study included 98 participants in the MPH group and 101 in the placebo group. Participants in the MPH group experienced gInternational journal of geriatric psychiatryAdverse effects of methylphenidate for apathy in patients with Alzheimer's disease (ADMET2 trial).PMC11265565U01 AG061357P30 AG066511UL1 TR001863R01 AG055132U54 AG065187P30 AG066507P30 AG072947R01 AG046543Lerner AJBrawman-Mintzer OHerrmann NCraft SZeng LGross ALPerin JShade DLevey APadala PRMintzer JEvan Dyck CHRosenberg PBLanctot KLPorsteinsson APfalseAdverse effects of methylphenidate for apathy in patients with Alzheimer's disease (ADMET2 trial).<h4>Objectives</h4>To examine clinically important adverse events (AEs) associated with methylphenidate (MPH) treatment of apathy in Alzheimer's Disease (AD) versus placebo, including weight loss, vital signs, falls, and insomnia.<h4>Methods</h4>The Apathy in Dementia Methylphenidate Trial 2 (ADMET2) trial was a multicenter randomized, placebo-controlled trial of MPH to treat apathy in individuals with apathy and AD. Participants in ADMET2 had vital signs and weight measured at monthly visits through 6 months. AEs, including insomnia, falls, and cardiovascular events, were reported at every visit by participants and families using a symptom checklist.<h4>Results</h4>The study included 98 participants in the MPH group and 101 in the placebo group. Participants in the MPH group experienced g2024-01-01T00:00:00Z2024 Jun2026-06-01T16:07:24.018Z2026-04-08T13:59:19.951ZS-EPMC112655653885852210.1002/gps.6108